Related Experiment Video

Updated: Mar 21, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Axitinib in the Treatment of Head and Neck Malignancies

Paul L Swiecicki1, Matthew Spector, Francis P Worden

  • 1Division of Hematology/ Oncology, Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Dr, SPC 5912, Ann Arbor, MI, USA. pswiecic@med.umich.edu.

Current Clinical Pharmacology
|May 19, 2016
PubMed

Insights

Targeted therapies like axitinib show promise for advanced head and neck cancers (thyroid and HNSCC) by inhibiting VEGFR. This review explores axitinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Head and neck cancers, including thyroid and HNSCC, present limited treatment options for advanced stages.
  • Current treatments often involve significant toxicities and suboptimal survival rates.
  • Dysregulated pathways like VEGFR and EGFR are implicated in head and neck cancers.

Purpose of the Study:

  • To review the role of Vascular Endothelial Growth Factor Receptor (VEGFR) in head and neck cancers.
  • To discuss recent clinical trials involving axitinib, a multi-tyrosine kinase inhibitor targeting VEGFR.
  • To analyze toxicity data and ongoing clinical trials for VEGFR-targeted therapies.

Main Methods:

  • Literature review of translational studies and clinical trials.
  • Analysis of VEGFR's role in head and neck cancer pathogenesis.
  • Evaluation of axitinib's efficacy and safety profile.

Main Results:

  • VEGFR signaling is a key pathway in head and neck cancers.
  • Axitinib demonstrates potential as a targeted therapy by inhibiting VEGFR-1, -2, and -3.
  • Toxicity data from axitinib trials are being assessed.

Conclusions:

  • Targeted inhibition of VEGFR pathways, such as with axitinib, represents a promising therapeutic strategy for advanced head and neck cancers.
  • Further clinical trials are necessary to fully establish the role and optimize the use of axitinib and similar agents.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
726
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786